| Grant date | Number of ACAs granted | Performance conditions(3) | Grant value (IFRS fair value) | Date of full vesting of all or part of the ACAs | Number of fully vested shares | First possible date of sale of a portion of these(4) |
|---|---|---|---|---|---|---|
| 17 April 2012(1) |
17 April 2012 (1)Number of ACAs granted 50,000 |
17 April 2012 (1)Performance conditions (3)Yes |
17 April 2012 (1)Grant value (IFRS fair value) 3,853,500 |
17 April 2012 (1)Date of full vesting of all or part of the ACAs 18 April 2016 |
17 April 2012 (1)Number of fully vested shares 50,000 |
17 April 2012 (1)First possible date of sale of a portion of these (4)18 April 2018 |
| 26 April 2013(1) |
26 April 2013(1) Number of ACAs granted 40,000 |
26 April 2013(1) Performance conditions (3)Yes |
26 April 2013(1) Grant value (IFRS fair value) 4,494,800 |
26 April 2013(1) Date of full vesting of all or part of the ACAs 27 April 2017 |
26 April 2013(1) Number of fully vested shares 40,000 |
26 April 2013(1) First possible date of sale of a portion of these (4)27 April 2019 |
| 17 April 2014(1) |
17 April 2014 (1)Number of ACAs granted 40,000 |
17 April 2014 (1)Performance conditions (3)Yes |
17 April 2014 (1)Grant value (IFRS fair value) 4,183,200 |
17 April 2014 (1)Date of full vesting of all or part of the ACAs 18 April 2018 |
17 April 2014 (1)Number of fully vested shares 40,000 |
17 April 2014 (1)First possible date of sale of a portion of these (4)18 April 2020 |
| 22 April 2015(1) |
22 April 2015 (1)Number of ACAs granted 32,000 |
22 April 2015 (1)Performance conditions (3)Yes |
22 April 2015 (1)Grant value (IFRS fair value) 5,167,680 |
22 April 2015 (1)Date of full vesting of all or part of the ACAs 23 April 2019 |
22 April 2015 (1)Number of fully vested shares 26,432 |
22 April 2015 (1)First possible date of sale of a portion of these (4)23 April 2021 |
| 20 April 2016(2) |
20 April 2016(2) Number of ACAs granted 32,000 |
20 April 2016(2) Performance conditions (3)Yes |
20 April 2016(2) Grant value (IFRS fair value) 4,938,240 |
20 April 2016(2) Date of full vesting of all or part of the ACAs 21 April 2020 |
20 April 2016(2) Number of fully vested shares 32,000 |
20 April 2016(2) First possible date of sale of a portion of these (4)21 April 2020 |
| 20 April 2017(2) |
20 April 2017(2) Number of ACAs granted 32,000 |
20 April 2017(2) Performance conditions (3)Yes |
20 April 2017(2) Grant value (IFRS fair value) 5,340,800 |
20 April 2017(2) Date of full vesting of all or part of the ACAs 21 April 2021 |
20 April 2017(2) Number of fully vested shares 26,544 |
20 April 2017(2) First possible date of sale of a portion of these (4)21 April 2021 |
| 17 April 2018(2) |
17 April 2018(2) Number of ACAs granted 30,000 |
17 April 2018(2) Performance conditions (3)Yes |
17 April 2018(2) Grant value (IFRS fair value) 5,285,100 |
17 April 2018(2) Date of full vesting of all or part of the ACAs 18 April 2022 |
17 April 2018(2) Number of fully vested shares 30,000 |
17 April 2018(2) First possible date of sale of a portion of these (4)18 April 2022 |
| 18 April 2019(2) |
18 April 2019(2) Number of ACAs granted 24,000 |
18 April 2019(2) Performance conditions (3)Yes |
18 April 2019(2) Grant value (IFRS fair value) 5,430,000 |
18 April 2019(2) Date of full vesting of all or part of the ACAs 19 April 2023 |
18 April 2019(2) Number of fully vested shares 24,000 |
18 April 2019(2) First possible date of sale of a portion of these (4)19 April 2023 |
At 31 December 2025, none of the shares granted to Jean-Paul Agon under ACAs Plans were still in their vesting period, because at that date the vesting periods of all the shares granted to him under ACAs Plans in the past had expired.
N/A.
| 2025 | 2024 | |||
|---|---|---|---|---|
| In € | Amounts allocated | Amounts paid | Amounts allocated | Amounts paid |
| Fixed remuneration | 2,300,000 | 2,300,000 | 2,000,000 | 2,000,000 |
| Annual variable remuneration | 2,762,000 | 2,048,500 | 2,048,500 | 2,250,000 |
| Exceptional remuneration | - | - | - | - |
| Remuneration for term of office as a Director | - | - | - | - |
| Benefits in kind | - | - | - | - |
| TOTAL | 5,062,000 | 4,348,500 | 4,048,500 | 4,250,000 |
| In € | 2025 | 2024 |
|---|---|---|
| Remuneration due in respect of the financial year |
Remuneration due in respect of the financial year 2025 5,062,000 |
Remuneration due in respect of the financial year 2024 4,048,500 |
| Value of performance shares granted during the financial year |
Value of performance shares granted during the financial year 2025 6,969,600 |
Value of performance shares granted during the financial year 2024 5,735,840 |
| TOTAL |
TOTAL 2025 12,031,600 |
TOTAL 2024 9,784,340 |
N/A.
N/A.
| Grant date | Number of ACAs granted | Performance conditions(1) | Grant value (IFRS fair value) | Date of full vesting of all or part of the ACAs | Number of fully vested shares | First possible date of sale of a portion of these(2) |
|---|---|---|---|---|---|---|
| 7 October 2021 |
7 October 2021 Number of ACAs granted 17,000 |
7 October 2021 Performance conditions (1)Yes |
7 October 2021 Grant value (IFRS fair value) 5,768,780 |
7 October 2021 Date of full vesting of all or part of the ACAs 8 October 2025 |
7 October 2021 Number of fully vested shares 17,000(3) |
7 October 2021 First possible date of sale of a portion of these (2)08 October 2025 |
| 13 October 2022 |
13 October 2022 Number of ACAs granted 20,000 |
13 October 2022 Performance conditions (1)Yes |
13 October 2022 Grant value (IFRS fair value) 6,066,600 |
13 October 2022 Date of full vesting of all or part of the ACAs 14 October 2026 |
13 October 2022 Number of fully vested shares N/A |
13 October 2022 First possible date of sale of a portion of these (2)14 October 2026 |
| 13 October 2023 |
13 October 2023 Number of ACAs granted 17,000 |
13 October 2023 Performance conditions (1)Yes |
13 October 2023 Grant value (IFRS fair value) 6,323,320 |
13 October 2023 Date of full vesting of all or part of the ACAs 14 October 2027 |
13 October 2023 Number of fully vested shares N/A |
13 October 2023 First possible date of sale of a portion of these (2)14 October 2027 |
| 10 October 2024 |
10 October 2024 Number of ACAs granted 16,000 |
10 October 2024 Performance conditions (1)Yes |
10 October 2024 Grant value (IFRS fair value) 5,735,840 |
10 October 2024 Date of full vesting of all or part of the ACAs 11 October 2028 |
10 October 2024 Number of fully vested shares N/A |
10 October 2024 First possible date of sale of a portion of these (2)11 October 2028 |
| 10 October 2025 |
10 October 2025 Number of ACAs granted 20,000 |
10 October 2025 Performance conditions (1)Yes |
10 October 2025 Grant value (IFRS fair value) 6,969,600 |
10 October 2025 Date of full vesting of all or part of the ACAs 11 October 2029 |
10 October 2025 Number of fully vested shares N/A |
10 October 2025 First possible date of sale of a portion of these (2)11 October 2029(4) |
| Grant date | Number of fully vested shares | Grant value (IFRS fair value) | Date of full vesting of all or part of the ACAs | Number of fully vested shares | First possible date of sale of a portion of these |
|---|---|---|---|---|---|
|
7 October 2021 |
7 October 2021 Number of fully vested shares 17,000 |
7 October 2021 Grant value (IFRS fair value) 5,768,780 |
7 October 2021 Date of full vesting of all or part of the ACAs 8 October 2025 |
7 October 2021 Number of fully vested shares 17,000(1) |
7 October 2021 First possible date of sale of a portion of these 8 October 2025(2) |